Victory Capital Management Inc. Acquires 3,977 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Victory Capital Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 92,891 shares of the biopharmaceutical company’s stock after acquiring an additional 3,977 shares during the quarter. Victory Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $81,585,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $31,000. MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $37,000. Finally, Sutton Wealth Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on REGN shares. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total transaction of $950,000.00. Following the sale, the executive vice president now owns 38,543 shares in the company, valued at $36,615,850. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the sale, the executive vice president now owns 13,431 shares of the company’s stock, valued at approximately $12,994,492.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph J. Larosa sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total transaction of $950,000.00. Following the completion of the transaction, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at $36,615,850. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,095 shares of company stock worth $9,664,476. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.1 %

NASDAQ REGN opened at $957.00 on Friday. The business’s fifty day moving average is $944.24 and its 200-day moving average is $895.54. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.40 and a quick ratio of 4.94. The stock has a market capitalization of $105.04 billion, a price-to-earnings ratio of 28.27, a PEG ratio of 2.69 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the company earned $10.96 earnings per share. The company’s quarterly revenue was up .6% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.